HK1017816A1 - Glial derived neurotrophic factor. - Google Patents

Glial derived neurotrophic factor.

Info

Publication number
HK1017816A1
HK1017816A1 HK98117977A HK98117977A HK1017816A1 HK 1017816 A1 HK1017816 A1 HK 1017816A1 HK 98117977 A HK98117977 A HK 98117977A HK 98117977 A HK98117977 A HK 98117977A HK 1017816 A1 HK1017816 A1 HK 1017816A1
Authority
HK
Hong Kong
Prior art keywords
gdnf
neurotrophic factor
derived neurotrophic
glial derived
vector
Prior art date
Application number
HK98117977A
Other languages
English (en)
Inventor
Leu-Fen H Lin
Franklin D Collins
Daniel H Doherty
Jack Lile
Susan Bektesh
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1017816A1 publication Critical patent/HK1017816A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
HK98117977A 1991-09-20 1998-12-28 Glial derived neurotrophic factor. HK1017816A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76468591A 1991-09-20 1991-09-20
US77410991A 1991-10-08 1991-10-08
US78842391A 1991-11-06 1991-11-06
US85541392A 1992-03-19 1992-03-19
PCT/US1992/007888 WO1993006116A1 (en) 1991-09-20 1992-09-17 Glial derived neurotrophic factor

Publications (1)

Publication Number Publication Date
HK1017816A1 true HK1017816A1 (en) 1999-11-26

Family

ID=27505700

Family Applications (2)

Application Number Title Priority Date Filing Date
HK98117977A HK1017816A1 (en) 1991-09-20 1998-12-28 Glial derived neurotrophic factor.
HK02108799.4A HK1047438A1 (zh) 1991-09-20 2002-12-03 神經膠質細胞營養因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02108799.4A HK1047438A1 (zh) 1991-09-20 2002-12-03 神經膠質細胞營養因子

Country Status (21)

Country Link
US (7) US7226758B1 (no)
EP (2) EP1243652A3 (no)
KR (1) KR100242093B1 (no)
AT (1) ATE275197T1 (no)
AU (2) AU679167B2 (no)
CA (1) CA2119463C (no)
DE (1) DE69233407T2 (no)
DK (1) DK0610254T3 (no)
ES (1) ES2225819T3 (no)
FI (1) FI117556B (no)
GE (1) GEP20002243B (no)
HK (2) HK1017816A1 (no)
HU (2) HU220795B1 (no)
IL (5) IL103223A (no)
MX (1) MX9205293A (no)
NO (1) NO321382B1 (no)
NZ (1) NZ244392A (no)
PT (1) PT100879B (no)
SG (1) SG48145A1 (no)
TW (1) TW401422B (no)
WO (1) WO1993006116A1 (no)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
JPH09503386A (ja) * 1993-09-01 1997-04-08 スタート テクノロジー パートナーシップ ニューロンの生存を促進するためのニューロン調節因子
WO1995017203A1 (en) * 1993-12-22 1995-06-29 The University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
WO1995029237A1 (en) * 1994-04-25 1995-11-02 Genentech, Inc. Cardiotrophin and uses therefor
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5853385A (en) * 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
AU1121997A (en) * 1995-11-29 1997-06-19 Amgen, Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
WO1997033911A1 (en) 1996-03-14 1997-09-18 Washington University Persephin and related growth factors
ATE247667T1 (de) 1996-03-14 2003-09-15 Genentech Inc Gdnf-rezeptor und dessen verwendung
US7015316B1 (en) 1996-03-14 2006-03-21 Washington University Polynucleotides encoding human persephin and related growth factors
US6222022B1 (en) * 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
AU2677797A (en) * 1996-04-25 1997-11-12 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
CA2262884C (en) * 1996-07-29 2004-06-08 Biopharm Gmbh Egf-like factor from chromaffin granules and glia cell-derived neurotrophic factor with survival-promoting activity on daergic neurons
ATE397061T1 (de) 1997-01-08 2008-06-15 Invitrogen Corp Verfahren zur herstellung von proteinen
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US6025157A (en) 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
US6372453B1 (en) 1997-02-18 2002-04-16 Genetech, Inc. Neurturin receptor
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
EP1304119A3 (en) * 1997-07-30 2004-01-21 Amgen Inc. Method for preventing and treating hearing loss using a neurturin protein product
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
DE69837600T2 (de) * 1997-08-05 2007-12-27 F. Hoffmann-La Roche Ag Aus einer menschlichen glial zelllinie-abgeleiteter promotor eines neurotrophischen faktors, diesen enthaltende vektoren und methoden zum screenen von verbindungen damit
AU765070B2 (en) 1998-03-23 2003-09-11 Genentech Inc. GFRalpha3 and its uses
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US6426065B1 (en) * 2000-11-07 2002-07-30 Clairol Incorporated Use of tris(hydroxymethyl)aminomethane in cold permanent waving processes
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US7379765B2 (en) * 2003-07-25 2008-05-27 Dexcom, Inc. Oxygen enhancing membrane systems for implantable devices
US8364229B2 (en) * 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7613491B2 (en) * 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US20030228295A1 (en) * 2002-04-25 2003-12-11 Svendsen Clive N. Use of human neural stem cells secreting GDNF for treatment of parkinson's and other neurodegenerative diseases
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
WO2007068784A1 (en) * 2005-12-14 2007-06-21 Licentia Ltd Novel neurotrophic factor protein and uses thereof
US7528112B2 (en) 2002-11-15 2009-05-05 Drexel University Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP1587545A2 (en) * 2003-01-13 2005-10-26 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
US7875293B2 (en) * 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
DK1636260T3 (da) 2003-06-10 2009-06-22 Biogen Idec Inc Forbedret udskillelse af Neublastin
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
WO2005021065A2 (en) * 2003-08-29 2005-03-10 New York University Indirect delivery of growth factors into the central nervous system
EP1660659A2 (en) * 2003-09-05 2006-05-31 Licentia, Ltd. Gdnf-related neuropeptides
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20050123526A1 (en) * 2003-12-01 2005-06-09 Medtronic Inc. Administration of growth factors for neurogenesis and gliagenesis
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
WO2005079257A2 (en) * 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
CA2568150A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
KR101241551B1 (ko) 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
KR20110126732A (ko) 2004-08-19 2011-11-23 바이오겐 아이덱 엠에이 인코포레이티드 뉴블라스틴 변형체
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
CN101287747A (zh) * 2005-08-16 2008-10-15 哥本哈根大学 Gdnf衍生肽
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
CA2627543A1 (en) * 2005-10-28 2007-05-03 Ns Gene A/S Implantable biocompatible immttnoisolatory vehicle for delivery of gdnf
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007120381A2 (en) * 2006-04-14 2007-10-25 Dexcom, Inc. Analyte sensor
BRPI0710800A2 (pt) 2006-04-25 2012-01-17 Univ California administração de fatores de crescimento para o tratamento de distúrbios de snc
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEUROTHERAPY OF HIGH MOLECULAR WEIGHT ENHANCED BY CONVECTION
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
KR100770440B1 (ko) * 2006-08-29 2007-10-26 삼성전기주식회사 질화물 반도체 발광소자
US8637459B2 (en) 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US20200037874A1 (en) 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
WO2008157308A2 (en) * 2007-06-13 2008-12-24 Wayne State University Board Of Governors A zwitterion solution for low-volume therapeutic delivery
CA2721134C (en) 2007-06-13 2017-02-07 Wayne State University Board Of Governors A baclofen solution for low-volume therapeutic delivery
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
EP4098177A1 (en) 2007-10-09 2022-12-07 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP3387993A3 (en) 2008-03-28 2018-11-14 Dexcom, Inc. Polymer membranes for continuous analyte sensors
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JP2011520914A (ja) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド 転移腫瘍の処置
ES2658626T3 (es) 2009-02-12 2018-03-12 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
EP2531206B1 (en) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
EP2569330B1 (en) 2010-05-11 2016-09-28 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
ES2613302T3 (es) 2010-12-02 2017-05-23 Neurotech Usa, Inc. Líneas celulares que segregan estructuras de anticuerpos anti-angiogénicas y receptores solubles y usos de los mismos
UA112981C2 (uk) 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
EP2747650B1 (en) 2011-08-26 2023-04-05 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP3711778B1 (en) 2011-12-02 2024-05-08 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
US9788765B2 (en) 2012-09-28 2017-10-17 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
BR112015013515A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
US9737250B2 (en) 2013-03-15 2017-08-22 Dexcom, Inc. Membrane for continuous analyte sensors
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10369329B2 (en) 2014-01-30 2019-08-06 Renishaw Plc Neurosurgical apparatus and method
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB201506052D0 (en) 2015-04-09 2015-05-27 Renishaw Plc Movement disorder
JP6850734B2 (ja) 2015-05-27 2021-03-31 ニューロテック ユーエスエー， インコーポレイテッド 眼の障害の処置のためのカプセル化細胞療法の使用
WO2017117472A1 (en) 2015-12-30 2017-07-06 Dexcom, Inc. Biointerface layer for analyte sensors
WO2018089702A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
JP2024510494A (ja) 2021-03-19 2024-03-07 デックスコム・インコーポレーテッド 分析物センサ用薬物放出膜
WO2023043908A1 (en) 2021-09-15 2023-03-23 Dexcom, Inc. Bioactive releasing membrane for analyte sensor
US20230240589A1 (en) 2022-02-02 2023-08-03 Dexcom, Inc. Sensing systems and methods for diagnosing, staging, treating, and assessing risks of liver disease using monitored analyte data
CA3234453A1 (en) 2022-02-23 2023-08-31 Dexcom, Inc. Sensing systems and methods for providing decision support around kidney health and/or diabetes
WO2023235443A1 (en) 2022-06-01 2023-12-07 Dexcom, Inc. Sensing systems and methods for diagnosing kidney disease
US20240090802A1 (en) 2022-09-02 2024-03-21 Dexcom, Inc. Continuous analyte sensor devices and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
ATE85080T1 (de) 1984-02-17 1993-02-15 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4886747A (en) 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU652537B2 (en) * 1988-11-04 1994-09-01 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5017735A (en) 1989-07-24 1991-05-21 Catalytica, Inc. Selective sorption of 2,6-diisopropylnaphthalene
AU6174490A (en) 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
CA2064787A1 (en) 1989-08-11 1991-02-12 Joe E. Springer Dopaminergic neurotrophic factor for treatment of parkinson's disease
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules

Also Published As

Publication number Publication date
HK1047438A1 (zh) 2003-02-21
AU2681192A (en) 1993-04-27
US6221376B1 (en) 2001-04-24
HU220795B1 (hu) 2002-05-28
US6093802A (en) 2000-07-25
IL140654A0 (en) 2002-02-10
US20020197675A1 (en) 2002-12-26
CA2119463A1 (en) 1993-04-01
KR940702505A (ko) 1994-08-20
EP0610254A1 (en) 1994-08-17
PT100879A (pt) 1994-02-28
EP0610254A4 (en) 1995-05-03
NZ244392A (en) 1995-03-28
FI117556B (fi) 2006-11-30
FI941285A0 (fi) 1994-03-18
CA2119463C (en) 2003-09-16
IL103223A (en) 2005-06-19
AU694387B2 (en) 1998-07-16
FI941285A (fi) 1994-03-18
IL121913A0 (en) 1998-03-10
EP1243652A2 (en) 2002-09-25
US5935795A (en) 1999-08-10
AU679167B2 (en) 1997-06-26
AU1900197A (en) 1997-09-18
DE69233407T2 (de) 2005-09-08
WO1993006116A1 (en) 1993-04-01
GEP20002243B (en) 2000-09-25
KR100242093B1 (ko) 2000-02-01
HUT66137A (en) 1994-09-28
DK0610254T3 (da) 2005-01-10
IL103223A0 (en) 1993-02-21
NO940922L (no) 1994-05-19
EP1243652A3 (en) 2003-03-26
IL140653A0 (en) 2002-02-10
SG48145A1 (en) 1998-04-17
US6015572A (en) 2000-01-18
MX9205293A (es) 1993-05-01
EP0610254B1 (en) 2004-09-01
NO321382B1 (no) 2006-05-02
PT100879B (pt) 1999-08-31
NO940922D0 (no) 1994-03-15
HU211984A9 (en) 1996-01-29
TW401422B (en) 2000-08-11
DE69233407D1 (de) 2004-10-07
HU9400717D0 (en) 1994-06-28
IL147488A0 (en) 2002-08-14
ES2225819T3 (es) 2005-03-16
US6362319B1 (en) 2002-03-26
ATE275197T1 (de) 2004-09-15
US7226758B1 (en) 2007-06-05

Similar Documents

Publication Publication Date Title
HUT66137A (en) Glial derived neurotrophic factor
DE69229572D1 (de) Gliazellen-aktivierender Faktor und dessen Herstellung
KR880700858A (ko) 재조합된 인간의 내피성 세포의 생장인자
EP0653940A4 (en) GLIALMITOGENIC FACTORS, THEIR PRODUCTION AND USE.
HUP9904239A2 (hu) Fehérjék nagymértékű expressziója
IL98205A0 (en) Type ii interleukin-1 receptors
CA2094027A1 (en) Osteogenic peptides
BG101408A (en) Analogs of keratinocyte growth factor
EP0559769A4 (en) Heparin binding mitogen with homology to epidermal growth factor (egf)
EP0268772A3 (en) Expression of biologically active factor xiii
CA2066618A1 (en) Plasmids containing dna encoding the amino acid sequence of tcf-ii, transformed cells with the plasmids, and production method of biologically active substance using the transformed cells
WO2000034474A3 (en) Growth factor homolog zvegf3
AU7681687A (en) Expression of platelet-derived growth factor and analogues
IE871871L (en) Cloning and expression of acidic fibroblast growth factor
DE69120626T2 (de) Polypeptid
AU2430588A (en) Mutant acidic fibroblast growth factor
EP0805204A3 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
CA2324649A1 (en) Human p51 genes and gene products thereof
EP0322084A3 (en) Tumor cell inhibition factor
DK171489A (da) Peptidderivater

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20120916